OLMA vs. HROW, CMPS, SIGA, ALT, CDMO, IGMS, ABUS, AVTE, STOK, and YMAB
Should you be buying Olema Pharmaceuticals stock or one of its competitors? The main competitors of Olema Pharmaceuticals include Harrow (HROW), COMPASS Pathways (CMPS), SIGA Technologies (SIGA), Altimmune (ALT), Avid Bioservices (CDMO), IGM Biosciences (IGMS), Arbutus Biopharma (ABUS), Aerovate Therapeutics (AVTE), Stoke Therapeutics (STOK), and Y-mAbs Therapeutics (YMAB). These companies are all part of the "pharmaceutical preparations" industry.
Olema Pharmaceuticals (NASDAQ:OLMA) and Harrow (NASDAQ:HROW) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their community ranking, risk, valuation, analyst recommendations, institutional ownership, media sentiment, earnings, profitability and dividends.
Olema Pharmaceuticals currently has a consensus target price of $22.00, indicating a potential upside of 123.58%. Harrow has a consensus target price of $29.80, indicating a potential upside of 77.80%. Given Olema Pharmaceuticals' higher possible upside, equities research analysts plainly believe Olema Pharmaceuticals is more favorable than Harrow.
Harrow received 57 more outperform votes than Olema Pharmaceuticals when rated by MarketBeat users. However, 61.54% of users gave Olema Pharmaceuticals an outperform vote while only 56.25% of users gave Harrow an outperform vote.
91.8% of Olema Pharmaceuticals shares are held by institutional investors. Comparatively, 72.8% of Harrow shares are held by institutional investors. 23.5% of Olema Pharmaceuticals shares are held by company insiders. Comparatively, 13.6% of Harrow shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Harrow has higher revenue and earnings than Olema Pharmaceuticals. Harrow is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Olema Pharmaceuticals has a beta of 2.1, indicating that its share price is 110% more volatile than the S&P 500. Comparatively, Harrow has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500.
In the previous week, Harrow had 8 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 33 mentions for Harrow and 25 mentions for Olema Pharmaceuticals. Olema Pharmaceuticals' average media sentiment score of 0.60 beat Harrow's score of 0.21 indicating that Olema Pharmaceuticals is being referred to more favorably in the media.
Olema Pharmaceuticals has a net margin of 0.00% compared to Harrow's net margin of -22.59%. Harrow's return on equity of -39.82% beat Olema Pharmaceuticals' return on equity.
Summary
Olema Pharmaceuticals beats Harrow on 9 of the 16 factors compared between the two stocks.
Get Olema Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for OLMA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OLMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Olema Pharmaceuticals Competitors List
Related Companies and Tools
